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BENEFITS OF MASSIVE WEIGHT LOSS ON SYMPTOMS, SYSTEMIC
INFLAMMATION AND CARTILAGE TURNOVER IN OBESE PATIENTS WITH
KNEE OSTEOARTHRITIS
P. Richette1, C. Poitou2, P. Garnero3, E. Vicaut1, J.-L. Bouillot4,
J.-M. Lacorte2, A. Basdevant2, K. Clément2, T. Bardin1, X. Chevalier5
1Hôpital Lariboisière, Paris, France; 2Hôpital La Pitié, Paris, France; 3Inserm
664, Lyon, France; 4Hôpital Hotel-Dieu, Paris, France; 5Hôpital Henri-Mondor,
Créteil, France
Purpose: To investigate the effect of massive weight loss on i) knee pain
and disability, ii) low-grade inﬂammation and metabolic status, and iii)
joint biomarkers in obese patients with knee osteoarthritis (OA).
Methods: 140 patients involved in a gastric surgery program were screened
for painful knee OA, and 44 were included (age 44±10.3 years, BMI 50.7±7.2
kg/m2). Clinical data and biological samples were collected before and 6
months after surgery.
Results: Before surgery, IL-6 levels were correlated with levels of hsCRP
(p=0.006) and Helix-II (p=0.01), a biomarker of cartilage turnover, and the
WOMAC function score (p=0.03). Surgery resulted in substantial decrease
in BMI (-20%). Levels of insulin and insulin resistance were decreased at
6 months. Knee pain decreased after surgery (24.5±21 vs. 50±26.6 mm;
p<0.001), and scores on all WOMAC subscales were improved. Levels of IL-
6 (p<0.0001), hsCRP (p<0.0001), orosomucoid (p<0.0001) and ﬁbrinogen
(p=0.04) were decreased after surgery. Weight loss resulted in a signiﬁcant
increase in levels of PIIANP (+32%; p=0.002), a biomarker of cartilage
synthesis, and a signiﬁcant decrease in that of COMP (-36%; p<0.001), a
biomarker of cartilage degradation. Changes in COMP concentration were
correlated with changes in insulin levels (p=0.02) and insulin resistance
(p=0.05).
Conclusions: In obese patients with knee OA, massive weight loss im-
proves pain and function and decreases low-grade inﬂammation. Moreover,
change in levels of joint biomarkers with weight loss suggests a structural
effect on cartilage
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EFFECTS OF LATERAL WEDGE INSOLES ON SYMPTOMS AND STRUCTURAL
DISEASE PROGRESSION IN MEDIAL KNEE OSTEOARTHRITIS: A 12-MONTH
RANDOMISED CONTROLLED TRIAL
K.L. Bennell1 , K.-A. Bowles1, C. Payne2, F.M. Cicuttini3, E. Williamson3,
A. Forbes3, F. Hanna3, R.S. Hinman1
1Univ. of Melbourne, Melbourne, Australia; 2La Trobe Univ., Melbourne,
Australia; 3Monash Univ., Melbourne, Australia
Purpose: Lateral wedge insoles inserted into shoes are an inexpensive,
easily available conservative treatment for knee OA that have been shown
to reduce medial knee joint load. The use of wedge insoles for OA symp-
tomatic beneﬁt is recommended by 13 out of 14 clinical guidelines and it
is proposed that by reducing knee load, wedge insoles may slow disease
progression. Given the limited number of clinical trials in this area, the
main purpose of this study was to investigate whether lateral wedge shoe
insoles lead to greater improvements in knee pain and physical function
and slower structural disease progression than control insoles in people
with medial knee OA.
Methods: This was a randomised participant- and assessor-blinded con-
trolled trial. 200 people aged 50 or more with a clinical and radiographic
diagnosis of mild-to-moderately severe (Kellgren & Lawrence Grade 2-
3) medial knee OA were recruited from the community in Melbourne,
Australia. Participants were randomised into two shoe insole groups: (1)
Full-length 5o lateral wedged insoles or (2) ﬂat control insoles. Both
groups were asked to wear the insoles daily for 12 months. The primary
symptomatic outcome was change in average knee pain in the past week
Abstract 006 – Table 1. ANCOVA results for primary outcomes of pain (cm) and medial tibial cartilage volume (mm3)
Outcome Baseline Follow-up Change (Follow-up – Baseline) Difference†
Wedge Control Wedge Control Wedge Control Est (95% CI) p
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Average pain 4 (2.1) 4.3 (1.9) 3.1 (2.1) 3.1 (2.3) -0.9 (2.1) -1.3 (2.4) 0.34 (-0.27, 0.95) 0.28
Cartilage volume* 1550.2 (451.7) 1520.0 (438.7) 1513.3 (480.1) 1482.8 (431.9) -43.5 (45.5) -43.4 (53.3) -0.38 (-15.38, 14.63) 0.96
*Change refers to the annualized change: (Follow-up minus baseline)/time between scans (yrs). †Adjusted for baseline value.
measured on an 11-point numeric rating scale and the primary structural
outcome was annualised change in medial tibial cartilage volume measured
from MRI. Secondary outcomes included measures of pain, function, health-
related quality of life, physical activity levels, and participant-perceived
rating of change in pain and function. Differences in mean change from
baseline to 52 weeks were compared between groups using analysis of
covariance adjusting for baseline values of the outcome measure. For
annualized change in medial cartilage volume, the data were also analysed
with additional covariates of age, gender, body mass index, medial tibial
bone size and MRI scanner as it was necessary to change scanners part way
through the study.
Results: 89 participants in the lateral wedge insoles group and 90 par-
ticipants in the control insoles group completed the 52-week trial (90%
overall completion rate). There were no baseline differences between the
insole groups except that the control group had a slightly higher BMI.
The results showed no signiﬁcant difference in the primary outcomes of
change in average pain and change in medial cartilage volume over the 52
weeks comparing the groups (Table 1). There was also no difference in the
secondary outcomes nor in the global rating of change. Multiple imputation
to account for missing values did not alter the results.
The mean (SD) duration of daily insole use was signiﬁcantly lower in the
lateral wedge than in the control insole group (6.8 (0.5) hours per day
vs 9.1 (0.4) hours, p<0.0001). More participants reported problems with
wedge insoles (42/89, 47%) than the control insoles (21/90, 23%). The lateral
wedge insoles were also rated as less comfortable than the control insoles.
Conclusions: Lateral wedge insoles worn for 12 months provide no ben-
eﬁts in alleviating symptoms or slowing disease progression (as indicated
by cartilage volume) over control insoles for older adults with mild to
moderately severe medial knee OA. The results do not support the current
recommendations of clinical guidelines.
Trial registration: ACTR12605000503628
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INTRAARTICULAR IL1-RA AFTER ACUTE KNEE INJURY DECREASES
BIOMARKERS OF INFLAMMATION AND IMPROVES PAIN AND FUNCTION
V. Byers Kraus, J. Birmingham, T. Stabler, S. Feng, D.C. Taylor,
C.T. Moorman, W.E. Garrett, A. Toth
Duke Univ., Durham, NC
Purpose: This pilot study evaluated the clinical therapeutic beneﬁts of
intraarticular IL-1 receptor antagonist (IL-1Ra) delivered during the ﬁrst
month after severe acute knee injury with anterior cruciate ligament (ACL)
tear.
Methods: Patients: This study was approved by the Institutional Review
Board and performed under a waiver of IND from the FDA. A total of
11 patients were treated within the ﬁrst 30 days of acute knee injury:
6 patients were randomized to intra-articular IL-1Ra (anakinra 150 mg
intra-articular) and 5 patients to saline placebo (equal volume 1 ml intra-
articular). Patients were recruited a mean 15±7 (SD) days from knee injury
(range 6-27 days). The mean age of participants was 24±4 (SD) years, (6
male, 5 female; 2 African American). Enrollment was limited to patients
under 40 years of age to try to insure the lack of underlying pre-existing
arthropathy. Clinical knee MRIs were performed revealing isolated anterior
cruciate ligament (ACL) tear (partial or full) in all patients: 3 patients
with isolated ACL tear; 3 patients with medial collateral ligament and ACL
tears; 4 patients with meniscal and ACL tears; and 1 patient with medial
collateral ligament, meniscal, and ACL tears.
Biomarker Assays: Samples of synovial ﬂuid (n=9 patients) and serum
(all patients) were available at baseline (prior to injection) and day 28
samples (prior to surgery) and analyzed for IL-1α, IL-1β, and IL-1Ra, using
commercial immunoassays (R&D Quantikine sandwich assays; intra- and
inter-assay CVs were <10%). Serum levels of hyaluronan (HA), associated
with joint inﬂammation, were quantiﬁed using a commercially available
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Abstract 007 – Table 1. Raw KOOS scores (non-normalized) were used for purposes of statistical analysis
KOOS Subscale Anakinra Treatment Placebo Treatment
Result Mean (SD) Mean (SD) Mean Change (SD) P value Result Mean (SD) Mean (SD) Mean Change (SD) P value
1st timepoint 2nd timepoint 1st timepoint 2nd timepoint
Pain 0> 4 16.7 (7.26) 12.8 (4.4) –3.8 (3.4) 0.043 0 = 4 15.4 (5.4) 12.6 (2.07) –0.6 (2.6) NS
ADL 0> 4 23.0 (14.4) 12.5 (7.1) –10.5 (7.7) 0.028 0 = 4 21.8 (7.3) 20.4 (3.0) –1.4 (8.6) NS
Total 0> 4 85.0 (31.2) 64.7 (25.8) –20.3 (6.7) 0.028 0 = 4 81.2 (16.5) 75.8 (6.2) –5.4 (16.5) NS
QOL 0 > 4 12.8 (4.3) 11.7 (3.9) –1.2 (1.3) 0.084 0 = 4 13.4 (1.8) 12.6 (2.2) –0.8 (1.9) NS
Other Symptoms 0 > 4 13.5 (5.9) 12.0 (7.1) –1.5 (2.1) 0.102 0 > 4 15.4 (5.4) 12.6 (5.3) –2.8 (2.6) 0.080
Sports Function 0 > 4 19 (1.3) 15.7 (4.9) –3.3 (3.7) 0.102 0 = 14 17.4 (3.7) 17.6 (2.4) 0.2 (3.6) NS
ADL 4 > 14 12.5 (7.1) 7.5 (6.2) –5 (4.24) 0.066 4 = 14 20.4 (3.0) 21.4 (7.2) 1 (7.9) NS
Total 4 > 14 64.7 (25.8) 48.3 (28.2) –15 (11.5) 0.066 4 = 14 75.8 (6.2) 77.4 (14.4) 1.6 (13.7) NS
Pain 4 > 14 12.8 (4.4) 9.5 (6.0) –3.0 (2.9) 0.109 4 = 14 12.6 (2.1) 12.8 (4.0) 0.2 (4.8) NS
QOL 4 > 14 11.7 (3.9) 10.3 (4.9) –1.25 (1.0) 0.102 4 < 14 12.6 (2.2) 13.2 (1.92) 0.6 (0.5) 0.083
Sports Function 4 > 14 15.7 (4.9) 12.8 (6.9) –5.0 (4.2) 0.102 4 = 14 17.6 (2.4) 17.4 (3.2) –0.2 (3.0) NS
For purposes of interpretation, 0 > 4 means score at Day 0 was greater than at Day 4, decline in severity over time.
Pain = KOOS pain; ADL = KOOS activities of daily living; QOL = KOOS quality of life subscale; Total = combination of 5 subscales: Pain, ADL and QOL and Other Symptoms and Function in
Sports and Recreation. P value by Wilcoxon rank sum test.
immunoassay (Corgenix; intra- and inter-assay CVs were 2% and 3%
respectively).
Functional Outcomes: The standardized KOOS questionnaire was obtained at
baseline (0), 4 days, 14 days, and 28 days or the day of surgery.
Statistical Analysis: The Wilcoxon rank sum test was used to evaluate the
change in KOOS from baseline to follow-up within a treatment group.
Two-tailed t-test was used to compare the change scores (pre-post synovial
ﬂuid concentrations) between placebo and drug treated groups.
Results: As shown in the table, the Anakinra group had substantially
greater improvement (∼1-3 s.d.) in key outcomes whereas the placebo
group had much less improvement (∼1/4 of s.d. on most outcomes).
Statistically signiﬁcant improvements in KOOS pain (p=0.04) and function
(activities of daily living, p=0.03), and total KOOS (p=0.03) were observed
in response to IL1-Ra, but not placebo. In the anakinra treated group this
corresponded to reductions in Pain of 23%, improvement in Activities of
Daily Living of 46%, and improvement in total KOOS of 24%; in contrast, the
placebo group changed only 4%, 6% and 7% for these outcomes respectively.
There were no adverse reactions in either the anakinra or saline placebo
treated groups.
Synovial ﬂuid IL-1α, IL-1β, and IL-1Ra concentrations exceeded serum
concentrations. IL-1α increased in all the placebo treated patients whereas
it decreased in 4 of 5 of the anakinra treated patients (p=0.05). Although
IL-1 and IL-1Ra declined dramatically over time post injury, there was no
signiﬁcant difference based on treatment. Serum HA decreased in all the
anakinra treated patients (n=6 pairs) from Time 1 to Time 2 (p=0.03) while
the change in the placebo treated patients was not signiﬁcant.
Conclusions: IL-1Ra decreased pain and improved function in our random-
ized pilot trial of acute knee injury. The decreases in serum HA and synovial
ﬂuid IL-1α in the IL-1Ra treated patients are consistent with a decrease in
synovial inﬂammation in acute knee injury in response to IL-1Ra therapy.
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BONE MARROW LESIONS, CARTILAGE LOSS, AND PAIN IN KNEE
OSTEOARTHRITIS: RESULTS FROM A RANDOMIZED CONTROLLED
CLINICAL TRIAL USINGMRI
L.M. Wildi1 , J.-P. Raynauld1, J. Martel-Pelletier1, F. Abram2, M. Dorais3,
J.-P. Pelletier1
1Univ. of Montreal Hosp. Res. Ctr. (CRCHUM), Montreal, QC, Canada;
2ArthroVision Inc., Montreal, QC, Canada; 3StatSci. Inc., Notre-Dame de
l’Île-Perrot, QC, Canada
Purpose: Magnetic resonance imaging (MRI)-detected subchondral bone
marrow lesions (BML) are frequently seen in osteoarthritis (OA) of the knee
depicting acute and chronic changes in this tissue. They have been shown
to predict cartilage loss and to correlate with pain. However, the literature
remains contradictory about the latter. Furthermore, we lack knowledge
about treatment effects on BML. The aim of this study was to assess, in a
multicentre randomized double-blind phase III clinical trial evaluating the
effect of licofelone vis-à-vis naproxen on knee OA, the presence of and
change in BML over time and their relationship to cartilage volume loss,
meniscal extrusion, and pain.
Methods: Knee OA patients were selected from the dataset of a recently
published randomized controlled trial [1]. One hundred and sixty-one
patients completed the study according to protocol. MRI was performed
at baseline, 6, 12, and 24 months to assess BML score and cartilage
volume changes over time. Pain levels were assessed using the WOMAC
questionnaire.
Results: Both treatment groups showed increased BML scores compared to
baseline in the global knee (both treatments combined: 0.71±1.85 [mean
±SD], p<0.0001, 24 months) and in all subregions except for the medial tib-
ial plateau where the BML score in the licofelone group remained stable at
12 (-0.01±0.37) and 24 months (-0.01±0.65) vis-à-vis an ongoing increase
in the naproxen group (0.15±0.58, p=0.04; 0.21±0.74, p=0.06, respectively).
In multivariate regression analysis, licofelone treatment predicted reduc-
tion in BML score in the medial tibial plateau (β estimate=-0.27, p=0.02) and
severe meniscal extrusion predicted progression (β estimate=0.26, p=0.03).
BML scores at baseline statistically correlated with cartilage volume (me-
dial, r=-0.24, p=0.002; lateral, r=-0.28, p=0.0003; femoropatellar, r=-0.28,
p=0.0003). In the global and medial compartments, BML score increases
correlated with cartilage loss at 12 months (r=-0.18, p=0.03; r=-0.19, p=0.02,
respectively). No correlation was found between BML and WOMAC pain
scores with the exception of an inverse correlation in the femoropatellar
compartment at 6 (r=-0.22, p=0.006) and 12 months (r=-0.24, p=0.002).
Conclusions: BML scores were found to increase over time, likely reﬂect-
ing an accumulation of chronic changes in subchondral bone tissue. The
correlation between BML and cartilage volume at baseline underlines a
close relationship between them. The reduction in BML might be due to
the unique action of licofelone not only on cyclooxygenases but also on
lipoxygenase. In contrast to previous reports, no positive relationship was
found between BML score (baseline or changes over time) and pain.
Reference
[1] Raynauld JP et al. Ann Rheum Dis 2009;68:938-47.
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THE ASSOCIATION OF PREVALENT CARTILAGE DAMAGE AND CARTILAGE
LOSS OVER TIMEWITH INCIDENT BONE MARROW EDEMA-LIKE LESIONS
AT THE TIBIOFEMORAL COMPARTMENTS: THE MOST STUDY
M.D. Crema1,2, F.W. Roemer1,3, K. Wang1, D.T. Felson1, M.D. Marra1,4,
M.C. Nevitt5 , J.A. Lynch5, J. Torner6, C.E. Lewis7, A. Guermazi1
1Boston Univ. Sch. of Med., Boston, MA; 2Inst. of Diagnostic Imaging (IDI) and
Radiology Div., Univ. of São Paulo at Ribeirão Preto, Ribeirão Preto, Brazil;
3Klinikum Augsburg, Augsburg, Germany; 4Inst. of Diagnostic Imaging (IDI),
Ribeirão Preto, Brazil; 5Univ. of California at San Francisco, San Francisco, CA;
6Univ. of Iowa, Iowa City, IA; 7Univ. of Alabama, Birmingham, AL
Purpose: Bone marrow edema-like lesions (BMLs), which histologically
represent bone damage, are predictors of cartilage loss and pain in knee
osteoarthritis (OA) and represent potential treatment targets. Loss of carti-
lage as part of OA may actually remove a tissue protecting underlying bone,
increasing loading and possibly damage to bone, leading to BMLs. The aim
of this study was to assess the association of prevalent cartilage damage
and cartilage loss over time with incident BMLs in the same subregion of
the knee.
Methods: The Multicenter Osteoarthritis (MOST) Study is a NIH-funded
observational study of individuals who have or are at risk for knee OA.
